Maravai LifeSciences Holdings, Inc. (MRVI) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.93B and a free-cash-flow yield of -6.2%. Over the most recent reported fiscal year, revenue declined 28.3%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 2.5/10
Clearly negative, short of the bottom band. As of Oct 3, 2026.
Momentum
Leading · +148.5% over 12 months ex. last
Top 20% of its market on the past year's move, per unit of the stock's own swings.
Shariah screen
Shariah Compliant
Debt and cash each under 30% of market cap, interest income under 5% of revenue, and no excluded industry — on the figures we hold, not a scholar's ruling.
Off its high
-83.0%
How far the last close sits under the highest price of the past five years.
Market cap
$2.93B
Trailing P/E
—
Price / book
5.8
Price / sales
14.1
FCF yield
-6.2%
Dividend yield
—
Gross margin
34.9%
Operating margin
-33.8%
Net margin
-37.1%
Revenue growth (YoY)
-28.3%
Revenue growth (3-yr annual)
-40.5%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.6
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
MRVI earnings
Next report: Nov 5, 2026 (Q3 2026, EPS estimate -$0.09).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 6, 2026
-$0.02
-$0.04
+50.0%
$51.44M
Q1 2026
May 7, 2026
$0.01
-$0.05
+120.0%
$65.84M
Q4 2025
Feb 25, 2026
-$0.04
-$0.07
+42.9%
$49.87M
Q3 2025
Nov 6, 2025
-$0.08
-$0.08
+0.0%
$41.63M
MRVI analyst price target
Median target $8.00 from 5 analysts, ranging $7.00 – $8.00.
Nama's AI scorecard currently rates Maravai LifeSciences Holdings, Inc. Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MRVI report earnings?
Maravai LifeSciences Holdings, Inc.'s next scheduled report is on Nov 5, 2026. Analysts expect EPS of -$0.09.
What is the MRVI price target?
The median analyst price target from 5 analysts is $8.00, with a range of $7.00 – $8.00.
Is MRVI Shariah compliant?
Nama's AAOIFI-style screen reads Maravai LifeSciences Holdings, Inc. as Shariah Compliant. Debt and cash each under 30% of market cap, interest income under 5% of revenue, and no excluded industry — on the figures we hold, not a scholar's ruling.